ADIAL PHARMACEUTICALS, INC. - FORM S-1/A - EX-23.1 - CONSENT OF FRIEDMAN LLP - April 13, 2018

Attached files

file filename
EX-10.23 - AMENDMENT #5 TO LICENSE AGREEMENT BETWEEN UNIVERSITY OF VIRGINIA PATENT FOUNDATI - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-23_adial.htm
S-1/A - AMENDMENT TO FORM S-1 - ADIAL PHARMACEUTICALS, INC.fs12017a4_adialpharma.htm
EX-10.29 - SETTLEMENT AGREEMENT DATED AS OF FEBRUARY 22, 2018 BY AND BETWEEN ADIAL PHARMACE - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-29_adial.htm
EX-10.28 - PERFORMANCE BONUS PLAN CANCELLATION - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-28_adial.htm
EX-10.27 - AMENDMENT TO CONSULTING AGREEMENT WITH JOSEPH TRULUCK DATED DECEMBER 1, 2018 - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-27_adial.htm
EX-10.26 - MEDICAL TRANSLATION SERVICES AGREEMENT BY AND BETWEEN ADIAL PHARMACEUTICALS, INC - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-26_adial.htm
EX-10.25 - BACKSTOP COMMITMENT AGREEMENT BETWEEN ADIAL PHARMACEUTICALS, INC. AND MVA 151 IN - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-25_adial.htm
EX-10.24 - FORM OF SECURITIES PURCHASE AGREEMENT BY AND AMONG ADIAL PHARMACEUTICALS, INC. A - ADIAL PHARMACEUTICALS, INC.fs12017a4ex10-24_adial.htm
EX-5.1 - OPINION OF GRACIN & MARLOW, LLP - ADIAL PHARMACEUTICALS, INC.fs12017a4ex5-1_adial.htm
EX-4.20(B) - STOCK PURCHASE WARRANT - ADIAL PHARMACEUTICALS, INC.fs12017a4ex4-20b_adial.htm
EX-4.20(A) - STOCK PURCHASE WARRANT - ADIAL PHARMACEUTICALS, INC.fs12017a4ex4-20a_adial.htm
EX-4.19 - SECURITY AGREEMENT - ADIAL PHARMACEUTICALS, INC.fs12017a4ex4-19_adial.htm
EX-4.18 - FORM OF SENIOR SECURED PROMISSORY NOTES DATED MARCH 1, 2018 BY AND BETWEEN ADIAL - ADIAL PHARMACEUTICALS, INC.fs12017a4ex4-18_adial.htm
EX-4.10 - GRANT INCENTIVE PLAN - ADIAL PHARMACEUTICALS, INC.fs12017a4ex4-10_adial.htm

 

Exhibit 23.1

 

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We hereby consent to the inclusion in this Amendment No. 4 to the Registration Statement on Form S-1 (File No. 333-220368) of our report dated April 13, 2018, which includes an explanatory paragraph as to the company’s ability to continue as going concern, with respect to the financial statements of Adial Pharmaceuticals, Inc. as of December 31, 2017 and 2016 and for the years then ended. We also consent to the reference to our firm under the heading “Experts” in such Registration Statement.

 

/s/ Friedman LLP

 

East Hanover, New Jersey

April 13, 2018

 

 

 

 

 

 

 

 

ADIAL PHARMACEUTICALS, INC. Reports